Milestones and successes from 10 years of HFG in Switzerland
The Human Research Act (HRA) was introduced in 2014 to ensure the safety and dignity of people participating in research. Before its introduction, different cantonal regulations existed in Switzerland, which led to confusion and legal uncertainty, noted the Swiss pharma trade group Interpharma.
The HRA was intended to create a uniform basis that would facilitate research while also improving the protection of participants.
The aim was clear: The Act on Research Involving Human Subjects (HFG), which came into force on January 1, 2014, was intended not only to ensure the protection of people participating in clinical trials, but also to improve the framework conditions for research.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze